Pharma Equity Group A/S Stock

Pharma Equity Group A/S Liabilities

The The Liabilities of Pharma Equity Group A/S (PEG.CO) as of Aug 15, 2026 is 13.43 M DKK. In the previous year, The Liabilities was 16.73 M DKK — a change of -19.75% (lower).

Liabilities

13.43 MDKK

YoY

-19.75%

Last updated:

In 2026, Pharma Equity Group A/S's total liabilities amounted to 13.43 M DKK, a -19.75% difference from the 16.73 M DKK total liabilities in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Pharma Equity Group A/S Stock analysis

What does Pharma Equity Group A/S do? Blue Vision A/S is a company specializing in the development, production, and marketing of underwater technology. It was founded in 1992 and is headquartered in Holstebro, Denmark. The company focuses on underwater lighting, underwater inspection cameras, and underwater communication. It specializes in manufacturing underwater lighting products for the offshore industry, ports, and shipping. It also produces underwater inspection cameras for inspecting underwater structures without the need for divers. In addition, the company has developed devices for underwater communication, which are crucial in the offshore industry and military sector. Blue Vision A/S emphasizes innovation and technology, holding patents and investing in digital technology to improve inspection systems. In summary, Blue Vision A/S specializes in underwater technology and offers solutions for the offshore industry, ports, and shipping. The company is committed to innovation and technology to provide the best solutions to its customers. Pharma Equity Group A/S is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Pharma Equity Group A/S's Liabilities

Pharma Equity Group A/S's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Pharma Equity Group A/S's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Pharma Equity Group A/S's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Pharma Equity Group A/S's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Pharma Equity Group A/S’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Pharma Equity Group A/S stock

The Liabilities of Pharma Equity Group A/S is 13.43 M DKK in 2026.

The Liabilities of Pharma Equity Group A/S changed from 16.73 M DKK to 13.43 M DKK, representing a -19.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Pharma Equity Group A/S since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's DKK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Pharma Equity Group A/S historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Pharma Equity Group A/S

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Pharma Equity Group A/S